Navigation Links
Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin,Emerging Growth Conference

SOUTH SAN FRANCISCO, Calif., July 03, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will present a company update at the C. E. Unterberg, Towbin Emerging Growth Conference on July 12, 2007 at 9:00 a.m. Eastern Time in New York, NY.

Interested parties may access the webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until July 26, 2007.

Option Award Disclosure

The Compensation Committee of the company's Board of Directors approved an employment commencement grant to Mr. Michael Coors, Director, Quality Assurance, of a non-qualified stock option to purchase 25,000 shares of Sunesis common stock, effective June 29, 2007. These option awards were granted without shareholder approval pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv) and with the following material terms: (a) an exercise price equal to the fair market value of the company's common stock on the grant date, (b) a term of ten years, and (c) a vesting schedule providing that the option is exercisable as to one-quarter of the total grant on the first anniversary of their hire, and one-forty-eighth of the total grant each month thereafter until the grant is fully vested.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-h
'"/>




Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:5/15/2008)...ts obtained with a newly cleared device to identif...erest that are associated with c...ss., May 15 /- InfraReDx, Inc. today,...Royal Oak, Mich., have,successfully used its LipiS...going a cardiac catheterization. This is the first...
(Date:5/15/2008)...tzerland, May 15 /- Ergonex Pharma to... Administration (FDA) has,granted orphan drug desi...y,arterial hypertension (PAH). Terguride is curren...trial in Europe., "The FDA,s grant of orphan drug...trengthens our development program by offering reg...
(Date:5/15/2008)..., Fla., May 15 /- Tigris Pharmaceutic...rative Research and,Development Agreement (CRADA) ...orate on clinical and preclinical development of A...opment. AFP-464 is converted to,metabolites which ...n and,apoptosis., This is part of a four-year CRA...
(Date:5/15/2008)...tunity Remains for an Antiplatelet Therapy that, C...he Combination of Plavix/Iscover and Aspirin, ... WALTHAM, Mass., May 15 /- Decision ... advisory firms for pharmaceutical and,healthcare ...ent offers,improvement in patient compared to Sano...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Purging the plantain pests in Africa 2284 1Purging the plantain pests in Africa 2284 2New understanding of how big molecules bind will lead to better drugs synthetic organic materials 12402 1New understanding of how big molecules bind will lead to better drugs synthetic organic materials 12402 2New understanding of how big molecules bind will lead to better drugs synthetic organic materials 12402 3Fast Food Ads Fueling Obesity Among Hispanic Kids 12399 1Fast Food Ads Fueling Obesity Among Hispanic Kids 12399 2First Lady Laura Bush Visits AED Netmark Malaria Control Project in Ghana 12394 1First Lady Laura Bush Visits AED Netmark Malaria Control Project in Ghana 12394 2
... -- Treatment of,coronary artery disease (CAD) app...g, according to a study published today in The,Ame...n rates for heart attacks (acute myocardial,infarc...ssibly due,to broader use of preventive treatments...ines in risk factors like smoking. , The study is ...
...d Play Key Role in the,Treatment of Influenza and ...ire-FirstCall/ --,ImmuneRegen BioSciences, a wholl.... , announced today that data obtained by,the Comp...that the,compound has potential value as a co-ther...ed in animal models of influenza and acute,radiati...
Other Medicine Technology:Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 2ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 3ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 4
(Date:5/16/2008)... Campaign to Visit Portland to Rally Residents to ... Milk Their Diets, PORTLAND, Ore., May 16 /PRNew...s and downs of different fad diets -- which seem t...hemlines. Yet, long-term success has been,slim. Tw...f Portland,residents -- remain overweight or obese...
(Date:5/16/2008)...First and Only Therapy Approved to Treat Both Type... Cholesterol Welchol Recently Add...6 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI),annou...her demonstrate that,Welchol(TM) (colesevelam HCl)...based therapy, significantly lowers blood glucose ...
(Date:5/16/2008)... Revolution Health CEO: ,We need to get the sy...wswire-FirstCall/ -- Internet visionary,turned e-h...ging trends in,public policy, technology and consu..."shake the snow globe," simultaneously creating di...ion in American health care., The America Online ...
(Date:5/16/2008)... ROCHESTER, Minn. -- Adding a second monoclonal a...reatment of diffuse large B-cell lymphoma, accordi...th Central Cancer Treatment Group (NCCTG) ( http:/...is were released May 15 as part of the 44th Annual...ogy. , Researchers found that 95 percent of pat...
Breaking Medicine News(10 mins):Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7Health News:'Case' in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution 2Health News:'Case' in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution 3Health News:'Case' in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution 4Health News:Adding epratuzumab to standard therapy 2
... for reduction on VAT for condoms, to be reduced f...bolishment of VAT on condoms, the best that can be...ked a re-categorization of condoms from a luxury i...hornberry, Labor MP for Islington South, has propo...
...rusalem researchers report that another health ben...lesterol in blood. As a result it reduces the inci...at heart patients who eat one grapefruit daily can...olesterol in their blood in comparison to patients...
...vement in the field of pharmacology; the number of...onsiderably over the recent years. It is however t...ad to disastrous consequences, including death. //...e ingredients that can interact or work against ea...
...ve disinfection of anthrax spores was highlighted ...tly. // It has now been found that anthrax spores ...ed disinfection methods due to their improved abil...r of water pipes. The researchers have therefore ...
Other Medicine News:Health News:One fruit that has captured the health benefit sector is Grapefruit! 2Health News:Drug Combinations Could Be Dangerous 2Health News:Anthrax Spores May Resist Water Treatment 2
A Merger of True Equals,Symbia T6, a True Point SPECTCT system, combines a dual-detector variable angle gamma camera with a six-slice CT scanner for advanced oncology, neurology, and cardiology app
...stent technology with no compromises. It's the ste... results. With S670's discrete, low-profile delive...excellent clinical results you want. S670, the fir...es. It's the stent that delivers like a balloon-wi...
The balloon catheter is a coaxial, dual balloon design and is made of PEBAX Material. Gas is contained in the inner balloon enhancing procedural safety. Radiopaque markings enhance the visibility of
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters.
Medicine Products: